LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert Perez, Cubist’ EVP and COO, will participate in a panel discussion on Tuesday, October 5, at 2 p.m. Eastern Time, at Citi’s 5th Annual Biotech Day being held at the Westin Waterfront Hotel in Boston. The panel will discuss the topic How to Kill Superbugs: Novel Antibiotics to Hit Drug Resistance Bacteria. (Live audio with slides webcast)
This panel discussion will be accessible live through Cubist’s website at www.cubist.com in the Investor Relations Conference Calendar section and will remain available there for a period of 30 days after the presentations.
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Infectious Diseases Pharmaceutical Research Science